![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Reports record results, screened more than 1 million people with Cologuard®, raises adjusted EBITDA guidance Second quarter highlights Delivered total second quarter revenue of $699 million, an...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | -0.004 | -28.5714285714 | 0.014 | 0.014 | 0.01 | 312500 | 0.0124 | DE |
12 | 0.001 | 11.1111111111 | 0.009 | 0.023 | 0.008 | 501580 | 0.01633858 | DE |
26 | 0.001 | 11.1111111111 | 0.009 | 0.023 | 0.008 | 501580 | 0.01633858 | DE |
52 | 0.001 | 11.1111111111 | 0.009 | 0.023 | 0.008 | 501580 | 0.01633858 | DE |
156 | 0.001 | 11.1111111111 | 0.009 | 0.023 | 0.008 | 501580 | 0.01633858 | DE |
260 | 0.001 | 11.1111111111 | 0.009 | 0.023 | 0.008 | 501580 | 0.01633858 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions